Incyte's stock rallies 9% after company says to buy back $1.67 billion of its own stock in Dutch auction tender
By Ciara Linnane
Biotech says board has approved share buyback authorization of up to $2 billion
Biotech Incyte Corp. said Monday its board has approved a share buyback of up to $2 billion and the company has commenced a modified Dutch auction tender for up to $1.67 billion worth.
The news sent the stock up 9% in early trade.
The offer "reflects our confidence in the future outlook of our business, the strength of our commercial product portfolio and our clinical development pipeline and Incyte's long-term value," Chief Executive Hervé Hoppenot said in prepared remarks.
The tender offer will be priced at no greater than $60 a share, which compares with the stock's (INCY) closing price Friday at $53.06.
In addition, the company has an agreement with Julian C. Baker, a member of its board, Felix J. Baker, and units affiliated with the two including funds advised by Baker Bros. Advisors LP, to repurchase up to $328 million of the company's common stock.
That will allow the Baker entities to maintain their current stake of about 16.4% of Incyte's outstanding stock. The Baker entities will pay the same price as in the tender offer.
The stock is down 8% in the year to date, while the S&P 500 SPX has gained 9.5%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-13-24 1016ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks